REFERENCES
- Labro MT. Immunomodulation by antibacterial agents. Is it clinically relevant? Drugs 1993; 45: 319–328.
- Labro MT. Immunomodulatory actions of antibacterial agents. Clin Immunother 1996; 6: 454–464.
- Labro MT. Interference of antibacterial agents with phagocyte functions: immunomodulation or «immuno-fairy tales. Clin Microbiol Rev. 2000; 13: 615–650.
- Labro MT. Effects of macrolides on host natural defences In: AJ Bryskier, JP Butzler, HC Neu, PM Tulkens, eds, Macrolides: chemistry, pharmacology and clinical uses. Paris: Arnette Blackwell, 1993: 389-408.
- Labro MT. Effects of macrolides on leukocytes and inflammation In: SH Zinner, IS Young, JF Acar, HC Neu, eds, Expanding indications for the new macrolides, azalides and streptogramins. New York: Marcel Dekker Inc. 1997: 101–116.
- Labro MT. Immunological effects of macrolides Curr Opin Infect Dis 1998; 11: 681–688.
- Labro MT. Anti-inflammatory activity of macrolides: a new therapeutic potential? J Antimicrob Chemother 1998; 41 (suppl. B): 37-46.
- Kirst HA. New macrolides: expanded horizons for an old class of antibiotics. J Antimicrob Chemother 1991; 28: 787–790.
- Fernandes PB. The macrolide revival: Thirty five years after erythromycin. Antimicrob Agents Chemother 1987; 4: 25–34.
- Bryskier A, Agouridas C, Chantot JF. Ketolides: new semi-synthetic 14-membered-ring macrolides. In: SH Zinner, LS Young, JF Acar, HC Neu, eds, Expanding indications for the new macrolides, azalides, and streptogramins. New York: Marcel Dekker, 39-50.
- Vazifeh D, Abdelghaffar H, Labro MT. Cellular accu-mulation of the new ketolide RU 64004 by human neu-trophils: comparison with that of azithromycin and rox-ithromycin. Antimicrob Agents Chemother 1997; 41: 2099-2107.
- Vazifeh D, Preira A, Bryskier A, Labro MT. Interactions between HMR 3647, a new ketolide, and human polymorphonuclear neutrophils. Antimicrob Agents Chemother 1998; 42: 1944-1951.
- Bryskier A, Agouridas C, Chantot JF. New medical tar-gets for macrolides. Exp Opin Investig Drugs 1994; 3: 405–410.
- Bryskier A, Agouridas C. Macrotides antibiotics and the heart. Exp Opin Investig Drugs 1994; 3: 1213–1219.
- Gurfinkel E, Bozovich G, Daroca A, Mautner B. Randomized trial of roxithromycin in non-Q-wave coronary syndromes. Roxis pilot study. Lancet 1997; 350: 404–407.
- Kobayashi H. Airway biofilm disease, its clinical mani-festation and therapeutic possibilities of macrolides. Am J Med 1995; 99: 26–30S.
- Jaffe A, Francis J, Rosenthal M, Buch A. Long term azithromycin may improve lung function in children with cystic fibrosis. Lancet 1998; 351–420.
- Shryock TR, Mortensen JE, Beeemholtz M. The effect of macrolides on the expression of bacterial virulence mecha-nisms. J Antimicrob Chemother 1998; 41: 505–512.
- Howe RA, Spencer RC. Macrotides for the treatment of Pseudomonas aeruginosa infections? J Antimicrob Chemother 1997; 40: 153–155.
- Scaglione F, Rossoni G. Comparative anti-inflammatory effects of roxithromycin, azithromycin and clarithromycin. J Antimicrob Chemother 1998; 41: 47–50.
- Abdelghaffar H, Vazifeh D, Labro MT. Erythromycin A-derived macrolides modify the functional activities of human neutrophils by altering the phospholipase D-phosphatidate phosphohydrolase transduction pathway. J Immunol 1997; 159: 3995–4005.
- Vazifeh D, Bryskier A, Labro MT. Effect of proinflam-matory cytokines on the interplay between roxithromycin, HMR 3647 or HMR 3004 and polymorphonuclear neu-trophils. Antimicrob Agents Chemother 2000; 44: 511–521.
- Altschuler L. Azithromycin, the multidrug-resistant protein, and cystic fibrosis. Lancet 1998; 351: 1286.
- Gant TW, O'Connor CK, Corbitt R, Thorgeisson U, Thorgeirsson S. In vivo induction of liver P-glycoprotein expression by xenobiotics in monkeys. Toxicol Appl Pharmacol 1995; 133: 269–76.